

09/787443

REC'D 13 OCT 1999

WIPO PCT



Kongeriget Danmark

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Patent application No.: PA 1998 01232

Date of filing: 29 Sept 1998

Applicant: All Applicants:

see attached documents

The attached photocopy is a true copy of the following document:

- The specification, claims, abstract and drawings as filed with the application on the filing date indicated above.



Erhvervsministeriet
Patentdirektoratet

TAASTRUP 05 Oct 1999



Lizzi Vester

Lizzi Vester
Head of Section

Patentansøgning

Se vejledning til de enkelte punkter på bagsiden

29 SEP. 1998

1. Gebyrer:

Ansøgningsgebær Kr. 3.000,-
 Kravgebær
 Tillægsgebær for hastebehandling
 Tillægsgebær for behandling af fremmedsproget beskrivelse

2. Ansøgers/fuldmægtigs referencenr.: P199801267 DK

3. International indleveringsdag:
Internationale ansøgningsnr.:
 Kapitel I
 Kapitel II
4. Ansøger (fulde navn og adresse): Flere ansøgere på side 2 og 3

Lars Christian Billmann Rønne
 Rektorparken 14, 3th.
 2450 København SV

5. Fuldmaægtig (fulde navn og adresse):

Hofman-Bang & Boutard, Lehmann & Ree A/S
 Hans Bekkevolds Allé 7
 DK-2900 Hellerup

6. Opfinder (fulde navn og adresse):

Lars Christian Billmann Rønne
 Rektorparken 14, 3th.
 2450 København SV

6a. Opfinder (fulde navn og adresse): Flere opfindere på side 2 og 3

Arne Holm
 Skodsborgparken 20, 2.tv
 2942 Skodsborg

12. Bilagsfortegnelse:

genpart af ansøgningsdokument
 fremmedsproget beskrivelse
 dansk beskrivelse i 2 eksemplarer
 sammendrag i 2 eksemplarer
 tegninger i 2 eksemplarer
 prioritetsdokument
 fuldmagt
 overdragelsesdokument
 Figur
 Figur

Fig. nr. ønskes publiceret sammen med sammendraget.

PA 1998 01232

8. Prioritetspåstand(e):

Dato	Land	Nr.
Dato	Land	Nr.
Dato	Land	Nr.

 Flere prioritetspåstande på side 29. Ansøgningen omfatter deponering af mikroorganisme-kultur(er), som angivet i patentlovens § 8a, stk. 1.10. Ansøgningen omfatter en sekvensliste.11. Ansøgningen er fremkommet ved deling eller udskillelse
Stamansøgningens nr.: Ansøgt løbedag:13.

Ansøgningen er tidligere
indleveret pr. telefax
den:

14. Dato og underskrift

29. september 1998

Hofman-Bang & Boutard, Lehmann & Ree A/S

Patentdirektoratet
 Helgeshøj Alle 81
 DK-2630 Taastrup
 Telefon 43 50 80 00
 Telefax 43 50 80 01
 Postgiro 8 989923



Ansøgere fortsat

Ansøger (fulde navn og adresse):

Arne Holm
Skodsborgparken 20, 2.tv
2942 Skodsborg

Ansøger (fulde navn og adresse):

Elisabeth Marianne Bock
Tonysvej 20
2920 Charlottenlund

Opfindere fortsat

Opfinder (fornavn, efternavn, adresse):

Elisabeth Marianne Bock
Tonysvej 20
2920 Charlottenlund

Opfinder (fornavn, efternavn, adresse):

Søren Østergaard
Borrebyvej 21
2700 Brønshøj

Opsindet (fornavn, efternavn, adresse):

Marianne Olsen
Mosevej 5
4000 Roskilde

Opfinder (fornavn, efternavn, adresse):

Prioritetspåstande fortsat

Ansøgere fortsat

Ansøger (fulde navn og adresse):

Søren Østergaard
Borrebyvej 21
2700 Brønshøj

Ansigter (fulde navn og adresse):

Marianne Olsen
Mosevej 5
Skt. Jørgensbjerg
40000 Roskilde

Opfindere fortsat

Opfinder (fornavn, efternavn, adresse):

Opfinder (fornavn, efternavn, adresse):

Opfinder (fornavn, efternavn, adresse):

Opfinder (fornavn, efternavn, adresse):

Prioritetspåstående fortsat

NCAM BINDING COMPOUNDS

The present invention relates to treatment of diseases and conditions of the central and peripheral nervous system, treatment of diseases and conditions of muscles and treatment of diseases and conditions of various organs. In particular, the present invention concerns new compounds which are capable of stimulating proliferation of and/or neurite outgrowth from cells presenting the neural cell adhesion molecule (NCAM), such as neurones. In a further aspect, the present invention relates to compositions, and medicaments as well as methods for treating normal, degenerated or damaged NCAM presenting cells.

BACKGROUND OF THE INVENTION

The brain and thus nerve cells and their function have during the last decades become an increasing subject of scientific investigations. Without doubt, the proper function of this complex system is extremely important for the proper function of the body and mind. It has been found that physical and mental malfunction can be related to i.a. abnormalities in level of signalling compounds, including neurotransmitters. Some malfunctions can be related to decay of nerve cells (neurones), connections between nerve cells and connections between muscle cells and nerve cells. This is e.g. the case in neurodegenerative diseases such as Alzheimers Disease, where death of nerve cells leads to senility.

During the development of the brain, connections between nerve cells (neurones) are formed. Such connections are necessary for communication between neurones to occur, allowing individual neurones to function together as a

(Edelman 90). Thus, NCAM is believed to be important for the development of the nervous system (Daston et al 1996) and various organs including the kidney (Lackie et al 1990), the liver (Knittel et al 1996), the bowel 5 (Romanska et al 1996), the heart (Gaardsvoll et al 1993), the gonads (Møller et al 1991), the pancreas (Møller et al 1992), and the muscles (Landmesser et al 1990). Therefore, ligands capable of influencing NCAM function may potentially be beneficial in conditions of impaired 10 development of these organs by inducing appropriate differentiation of target cells (Walsh et al 1990). In the brain, the role of NCAM has been supported by knock out mice which have altered development of certain brain regions, including the olfactory system, the hippocampus, 15 the cerebellum and the retina (Cremer et al 1994). In these tissues, the lack of NCAM expression impairs migration of cells (Ono et al 1994) and outgrowth and fasciculation of neurites (Cremer et al 1997) which in turn leads to altered synaptogenesis and morphological 20 and functional changes. Transgenic mice with a change in the NCAM gene to produce only soluble NCAM forms die before birth further indicating that NCAM functions have great potential to interfere with development (Rabinowitz et al 1996).

25 In the mature nervous system, NCAM have been shown to be important for the plasticity of neuronal connections associated with regeneration, learning and memory (Fields et al 1996). In the peripheral nervous system, NCAM is 30 believed to be necessary for outgrowth of nerve fibres and formation of nerve-muscle connections in regeneration after damage including lesions (Nieke et al 1985) and stroke (Jucker et al 1995).

35 Moreover, NCAM is presumably involved in ageing-related impairments in the ability to regenerate peripheral

nerves and nerve-muscle connections (Olsen et al 1995) as well as in a number of degenerative muscle diseases (Walsh et al 1985). A similar role of NCAM has been observed in the central nervous system where NCAM is believed to be important for neuritic outgrowth, fasciculation, branching and probably target recognition associated with regeneration (Daniloff et al 1986). In addition, NCAM-MAG double knock out mice have shown that NCAM is also necessary for myelination of neuronal fibres which is of crucial importance for neuronal function (Carenini et al 1997). In learning, subtle remodelling of neuronal connections is necessary for the stabilisation of a memory trace and it has been shown that NCAM expression changes concomitant with such changes (Doyle et al 1992). Moreover, interference with NCAM function by antibodies or in knock out mice impairs the ability to learn (Luthi et al., 1994; Rønn et al., 1995; Scholey et al 1993). From knock out mice, it has become evident that NCAM is also involved in other behavioural phenomena. Thus, NCAM knock out mice have altered circadian rhythm (Shen et al 1997) and males shown increased aggression (Stork et al 1997). In humans, elevated levels of soluble NCAM forms have been shown in schizophrenia (van Kammen et al 1998) and sclerosis (Massaro et al 1987) suggesting that NCAM could be of importance for these diseases.

NCAM is found in three main forms of which two are transmembrane forms while the third form is attached to the membrane by a lipid anchor (see FIGURE 1). All three forms have the same structure extracellularly consisting of five immunoglobulin domains (Ig domains) and two fibronectin like domains (FnIII domains). A precursor form of the NCAM contains a signal sequence. The amino acid sequence of 140 Kd isoform precursor of human NCAM is shown in Figure 17. The Ig domains are numbered one to five from the N-terminal, that is Ig1 to Ig5. The

fibronectin domains are likewise called FnIII1 and FnIII2. In addition to mediating cell adhesion, NCAM affect signal transduction in cells (Schuch et al 1989). When an NCAM molecule at the cell surface binds to 5 another cell, a signal is transmitted to the interior of the cell (transmembrane signalling). Within the cell, a signalling cascade is activated that subsequently influences the behaviour of the cell. It has been shown that signalling initiated by NCAM binding can stimulate 10 neurite extension (Doherty et al., 1996).

It is unclear, which of the NCAM domains mediate cell adhesion and signal transduction. The generally accepted hypothesis predicts that homophilic NCAM adhesion is 15 mediated by a transreciprocal interaction between the Ig3 domains of two opposing NCAM molecules. Considerable evidence supports this notion and a putative binding site has been identified (Rao et al 1992, Rao et al 1994, Sandig et al 1994). Also ligands affecting the Ig3 domain 20 have been shown to inhibit NCAM mediated cell adhesion. A recent hypothesis predicts that not only the Ig3 but all five Ig-domains mediate homophilic NCAM binding (Ranheim 96). According to this hypothesis, Ig1 of one NCAM molecule binds to Ig5 of another NCAM molecule, Ig2 binds 25 Ig4 and Ig3 binds to Ig3. Thus these two theories of NCAM binding are partially overlapping. The present inventors and their colleagues have recently proposed that a double reciprocal interaction between Ig1 and Ig2 domains of two opposing NCAM molecules may mediate homophilic NCAM 30 binding (Thomsen et al. (1996), Kiselyov et al. (1997), Rønn (1997). Rønn observed an inhibition of aggregation of neurones in a culture of hippocampal cells when adding small peptides which were previously identified as capable of binding to the NCAM Ig1 domain. An additional 35 stimulation of neurite outgrowth was also seen. Rønn neither disclosed the sequence of the peptides studies

nor suggested an exploitation of his observations in medical treatment. In conclusion, the mechanism of homophilic NCAM binding is still a matter of debate although most researchers in the field favour the 5 hypothesis of a an reciprocal interaction between all five Ig domains or at least between the Ig3 domains of two opposing NCAM molecules.

Antibodies against NCAM, purified NCAM protein and 10 recombinant NCAM domains have been shown to induce signal transduction in certain cells. High concentrations of NCAM antibody can induce a transient calcium increase as well as a pH change in some but not all neuronal cells (Schuch et al 1989). The recombinant NCAM domains Ig1 and 15 Ig2 and the combined domains Ig1-5 can induce a similar transient calcium increase and change in pH in certain cells (Frei et al 1992). When used as a substrate or expressed by a monolayer of cells, the NCAM protein can stimulate neurite extension. The response depends on an 20 interaction between the FnIII domains of NCAM with fibroblast growth factor (FGF)-receptors (Doherty et al 1996). In addition, an interaction between the cytoplasmic part of NCAM with the tyrosine kinase fyn is 25 of importance for neurite outgrowth (Beggs et al 1997). Also, recombinant NCAM domains immobilised to the substratum can stimulate neurite extension, branching of neurites or fasciculation of neurites. Thus the FnIII 30 domains of NCAM can increase branching of neurites when used as a substratum (Stahlhut et al 1997, Kasper et al 1996). Moreover, the FnIII domains have been reported to be the most potent NCAM domains to influence cell spreading and neurite outgrowth. Ig 1-5 also influenced 35 these processes but less potently than the FnIII domains (Frei et al 1992). In contrast, Ig1 and Ig2 most potently promoted cell adhesion and cell migration in this study (Frei et al 1992). Frei et al also observed stimulation

of neurite outgrowth by the isolated NCAM domains Ig3, Ig4, Ig5, FnIII,1 and FnIII,2, but not by Ig1 and Ig2. A sequence located between the Ig5 and the FnIII,1 domains have been shown to be important for fasciculation of 5 neurites (Pollerberg et al 1993). The Ig5 domain of NCAM is of major importance for neurite outgrowth due to the presence or absence of the sugar chains polysialic acid (PSA) on this domain (Rutishauser et al 1996). Likewise, the Ig4 domain is important due to the presence or 10 absence of the alternatively spliced domain VASE (Doherty et al 1992). Synthetic peptides corresponding to the VASE sequence have been shown to interfere with NCAM stimulated neurite outgrowth (Lahrtz et al 1997). Moreover, the NCAM Ig4 domain is presumed to bind another 15 cell adhesion molecule, L1, and thereby to influence neurite outgrowth (Horstkorte et al 1993). In contrast to the effect of immobilised reagents, NCAM antibodies or recombinant domains inhibit neurite outgrowth when added 20 in solution. Peptides corresponding to the presumed homophilic binding site in Ig3 or mutations in this sequence in the Ig3 domain have been shown to inhibit neurite outgrowth stimulated by NCAM (Sandig et al 1994).

However, an antibody against NCAM has recently been shown 25 to stimulate neurite outgrowth (US patent no. 5667978). This antibody recognises the Ig3 domain of NCAM. All NCAM domains have moreover been shown to influence proliferation of glial cells, neuroblastoma cells and fibroblasts, the Ig3 domain being the most potent. This 30 function has been shown to require interaction with MAP kinase activity (Krushel 1998). It has been shown that various inhibitory ligands of the NCAM Ig3 domain, including small peptides corresponding to parts of the Ig3 domain sequence, can inhibit glial proliferation (WO 35 96/18103).

These data suggest, that the NCAM protein or NCAM ligands could potentially influence functions of the nervous system and other tissues. Inhibiting glial proliferation would potentially be beneficial in degenerative conditions (WO 96/18103, US 5 625 040, US 5 667 978). Alternatively, if NCAM functions, particularly the induction of neurite outgrowth, could be stimulated, a beneficial effect on brain function would be possible. A stimulation of certain in vitro NCAM functions has been described for an antibody against NCAM Ig3 (US 5 667 978). However, no small ligands of NCAM with significant stimulatory effect on NCAM functions has been described. Moreover, it is not evident to which NCAM domain such a ligand should be targeted. Most evidence points at the NCAM Ig3 domain as the crucial domain for homophilic binding while the cytoplasmic part of NCAM together with the FnIII domains are presumed to be most important for interactions with signalling molecules.

In the Ph.D. thesis NCAM and Neural Plasticity (Rønn 1997), the role of NCAM in neural plasticity was studied. Different assays (test systems), including aggregation of neural cells, neurite extension and long-term potentiation (LTP) were used to study how the role or effect of NCAM was influenced by NCAM antibodies, NCAM fusion proteins and other NCAM ligands. Presumed NCAM ligands selected from a random peptide library were studied. The peptides were found to be able to bind Ig1. One specific peptide, which is not characterised further in the thesis, was shown to inhibit aggregation of neural cells and to stimulate neurite outgrowth. It is concluded that such ligands might be a valuable tool in the continued attempts to clarify the role of NCAM in the developing nervous system as well as in synaptic plasticity. A possible medical use of the investigated peptides is neither an object of the thesis nor suggested

therein. Furthermore, the thesis does not disclose the sequences of the investigated peptides.

US 5 625 040 relates to chondroitin sulphate proteoglycan (Phosphacan) and its use in enhancing regeneration of nerves by binding to NCAM. The Phosphacan sequence is 1616 amino acid residues long. Recombinant Phosphacan was obtained by cloning the encoding gene in a suitable vector. The gene was isolated using primers chosen in accordance with the identified amino acid sequences of some proteolytic fragments of Phosphacan. None of the fragments was suggested to possess a biological effect per se.

A stimulatory effect on the potential for neurite extension may be expected to have a beneficial effect in functions of the nervous system requiring plasticity of connections between nerve cells. Such functions include learning and memory and regeneration. It is therefore of considerable interest to identify substances with the capability to influence NCAM mediated signalling.

SUMMARY OF THE INVENTION

In accordance with the present invention, novel compounds are provided, which promote extension of neurites in the central and peripheral nervous system.

More specifically, the invention concerns compounds which bind to the NCAM Ig1 domain and are capable of stimulating neurite outgrowth from and/or proliferation of NCAM presenting cells. These compounds include the group comprising the NCAM Ig2 polypeptide and fragments and mimics thereof. Such compounds may be composed of natural occurring as well as synthetic amino acids,

peptide nucleic acids (PNA) monomers and/or peptidomimetics.

In particular, the compound may be a peptide which binds 5 to the 1st domain of NCAM (NCAM Ig1) through a binding motif which comprises at least 2 basic amino acid residues, preferably at least 2 basic amino acid residues within a sequence of 10 amino acid residues and more preferably at least 2 basic amino acid residues within a 10 sequence of 3 amino acid residues.

Interesting peptides comprise the sequence:

15 $(Xaa^+)_m - (Xaa)_p - (Xaa^+)_r - (Xaa^1)_r - (Xaa)_q - (Xaa^+)_n,$

wherein Xaa^+ is a basic amino acid residue,
 Xaa^1 is any amino acid residue,
 Xaa is any amino acid residue, and
20 m, n, p, q and r independently are 0 or 1,

and wherein the basic amino acid residues preferably are lysine or arginine and r preferably is 1.

25 The nature of the amino acid residues Xaa and Xaa^1 does not seem to be important. It appears that they may be any amino acid residue. However, Xaa^1 is preferably proline (P) or glutamic acid (E).

30 In even more preferred peptides r is 1 and at least one of m and n is 1.

Preferred peptides of the invention comprise the sequence $(K/R)_{0-1}-K/R-X-K/R$, wherein X has the same meaning as 35 Xaa^1 , suitably the sequence $K/R-K/R-X-K/R$ or $K/R-X-K/R$, more suitably the sequence $K/R-P-K/R$, $K/R-K/R-P-K/R$,

K/R-K/R-E-K/R or K/R-K/R-E-K/R most suitably the sequence K-P-K, K-K-P-K, K-K-E-K or K-K-E-R. Examples are the sequences A-S-K-K-P-K-R-N-I-K-A (SEQ ID NO:1), A-K-K-E-R-Q-R-K-D-T-Q (SEQ ID NO:2), and A-R-A-L-N-W-G-A-K-P-K (SEQ 5 ID NO:3).

The abbreviations of the amino acids follow the normal three and one letter codes: alanine (Ala,A), arginine (Arg,R), asparagine (Asn,N), aspartic acid (Asp,D), 10 cysteine (Cys,C), glutamic acid (Glu,E), glutamine (Gln,Q), glycine (Gly,G), histidine (His,H), Isoleucine (Ile,I), leucine (Leu,L), lysine (Lys,K), methionine (Met,M), phenylalanine (Phe,F), proline (Pro,P), serine (Ser,S), threonine (Thr,T), tryptophan (Trp,W), tyrosine 15 (Tyr,Y) and valine (Val,V).

In the present context, the term amino acid is intended to comprise naturally occurring amino acids as well as non-natural occurring amino acids. Non-natural occurring 20 amino acids are i.a. modified naturally occurring amino acids.

The peptides may be modified, for example by acetylation.

25 The invention also concerns compounds which are anti-NCAM Ig1 antibodies, which mimic the binding of the NCAM Ig2 domain to the Ig1 domain. Such non-peptide molecules are e.g. PNAs or peptidomimetics. Examples of peptidomimetics are given in Marshall, G.R., Tetrahedron 49, 3547-3558 30 (1993), and include oligo(N-substituted glycines), oligocarbamates, oligosulphones and oligosulfoxides.

The invention further concerns compounds which are non-peptide molecules, which mimic the binding of the NCAM 35 Ig2 domain to the Ig1 domain.

The invention even further concerns the NCAM Ig2 polypeptide, fragments or mimics thereof for use in the treatment of normal, degenerated or damaged NCAM presenting cells, said treatment consisting of stimulating neurite outgrowth from and/or proliferation of NCAM presenting cells.

5 The treatment may be a treatment of diseases and 10 conditions of the central and peripheral nervous system, the muscles or various organs. The treatment may also be a stimulation of learning and memory.

15 In the present context, the term conditions is intended to cover any condition in need of treatment, whatever the need is in connection with a damage, disease or expected disease or in connection with a stimulation and/or improvement of normal conditions.

20 The invention also concerns the use of the NCAM Ig2 polypeptide or fragments or mimics thereof in the manufacture of a medicament for the treatment of normal, degenerated or damaged NCAM presenting cells.

25 The invention further concerns pharmaceutical compositions comprising one or more of the compounds according to the invention.

30 Further, the invention concerns a method of treating normal, degenerated or damaged NCAM presenting cells which method comprises administration of an effective amount of one or more of the compounds according to the invention.

35 The treatment may be a treatment of diseases or conditions of the central and peripheral nervous system,

such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as 5 multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; of diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as genetic or traumatic 10 atrophic muscle disorders; of diseases or conditions of various organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis or of the heart, 15 liver or bowel. The treatment may also be a stimulation of the ability to learn and/or of the memory.

The invention also concerns a prosthetic nerve guide, which guide comprises one or more of the compounds 20 according to the invention.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 shows the different forms of the neural cell 25 adhesion molecule, NCAM. A) The main forms of NCAM all have similar extracellular parts consisting of five immunoglobulin-domains (Ig-domains) and two Fibronectin type III-domains (FnIII-domains). Three trans-membrane or membrane attached forms (NCAM-120, -140 and -180) are 30 generated by alternative splicing. In addition, various soluble NCAM forms (NCAMs) exist. B) Individual NCAM-domains are numbered from the N-terminal (NH₂), the most N-terminal domain being termed NCAM Ig1. An important alternatively spliced exon is the VASE exon that can be 35 inserted in the region encoding the Ig4 domain of NCAM.

The Ig5 domain can be glycosylated with polysialic acid (PSA).

Fig. 2 shows an identification of bead-coupled peptides binding NCAM domains. A) Libraries of bead-coupled decapeptides are incubated with the recombinant NCAM Ig1 domain. Beads that bind NCAM Ig1 are visualised by a staining reaction. Stained beads are isolated and microsequenced (Example 3 and 4). B) After evaluation of binding sequences, peptides corresponding to these sequences are synthesised as monomers, dendrimers (4-mers) or BSA-coupled 20-mers (Example 5). C) Structure of peptide dendrimers. Four peptide-monomers (peptide) are coupled to a backbone consisting of three lysines.

Fig. 3 shows single hippocampal cells (Example 7 (2)) maintained in the absence (A) or presence (B) of C3d (5.4×10^{-7} M).

Fig. 4 shows the peptide-sequences identified from combinatorial peptide libraries. A) 22 sequences identified from screening a combinatorial library with NCAM Ig1. B) Peptides from A) comprising parts of the motif K/R-K/R-P-K/R-N/S emphasised in bold. The C3 peptide is underlined. C) Peptides comprising parts of the motif K/R-K/R-E-K/R-X-K/R-K/R emphasised in bold. The D3 peptide is underlined. D) Peptides containing the motif G-X-K/R-P-K/R emphasised in bold. The D4 peptide is underlined.

Fig. 5 shows the number of aggregates of primary hippocampal neurones formed after 24 h in culture in the presence of C3 dendrimer in concentrations of 1.07 μ M and 2.15 μ M (Example 7). The observed increase in the number of aggregates formed reflects an inhibition of the aggregation-process.

Fig. 6 shows the number of neuronal processes from primary hippocampal neurones formed after 24 h in culture in the presence of C3 dendrimer in concentrations of 1.07 5 μ M and 2.15 μ M (Example 7).

Fig. 7 gives a summary of the NCAM Ig1 binding peptides and their effect on neurite-outgrowth and aggregation in cell cultures of primary hippocampal neurones. Effect on neurite-outgrowth is measured in cultures of dissociated neurones as described in example 7 (2). For neur, 0 indicates no effect, + indicates stimulatory effect, ++ indicates strong stimulatory effect on neurite outgrowth. For agg, 0 indicates no effect, - indicates inhibitory effect, -- indicates strong inhibitory effect on aggregation, the inhibitory effect being reflected as an increased number of aggregates formed. The peptide names and/or numbers correspond to peptides of the sequences indicated in the figure. The peptides are all tested as 10 dendrimers.

15

20

Fig. 8 shows the effect of C3 dendrimer on neurite outgrowth in cocultures of neurones and fibroblasts (Example 7). Primary hippocampal neurones were grown on 25 monolayers of fibroblasts with (LBN) or without (LVN) NCAM-140 expression. Neurite-outgrowth was increased on LBN fibroblast-monolayers compared to LVN fibroblast monolayers. This increase was inhibited by C3d in 0.54 or 30 5.4 μ M. On LVN monolayers, C3d stimulated neurite outgrowth.

Fig. 9 shows the effect of D3 and D4 dendrimers on neurite outgrowth from primary hippocampal neurones in the indicated doses in μ M.

Fig. 10 shows the effect of C3 peptide dendrimer on neurite outgrowth from primary hippocampal neurones in the indicated doses in μM . Neurite outgrowth is measured as the mean length of the longest neurite (axon length). Primary hippocampal neurones from E18 rats were maintained for 21 h on fibronectin.

Fig. 11. shows neurite outgrowth measured from neurones maintained on plastic. Effect of C3d and control peptides (see Fig 7) on neurite outgrowth in a concentration of 10 $0.54 \mu\text{M}$.

Fig. 12 shows the effect of various inhibitors of signal transduction on neurite outgrowth from primary hippocampal neurones maintained on fibronectin stimulated by C3d ($0.54 \mu\text{M}$, see Example 7 2). Ver: verapamil (10 μM), Cono: omega-conotoxin GVIA ($0.27 \mu\text{M}$), ploop1: NCAM Ig1 prepared in *Pichia pastoris* as described in example 1, $0.54 \mu\text{M}$.

Fig. 13 shows the effect of various inhibitors of signal transduction on neurite outgrowth from primary hippocampal neurones maintained on fibronectin stimulated by C3d ($0.54 \mu\text{M}$, see Example 7). Erb: erbstatin analogue ($0.2 \mu\text{M}$), Pertus: Pertussis toxin ($1 \mu\text{g/ml}$), CHD: peptide corresponding to CAM homology domain in FGF-R (175 or 350 μM)

Fig. 14 shows the effect of NCAM Ig2, prepared in *Pichia pastoris* as described in example 2, on neurite outgrowth from primary hippocampal neurones maintained on fibronectin. NCAM Ig2 was added in the indicated concentrations in $\mu\text{g/ml}$ ($1 \mu\text{g/ml}$ corresponds to $0.1 \mu\text{M}$). Neurite outgrowth is measured as the mean length of the longest neurite (axon length).

Fig. 15 shows the effect of C3d and NCAM Ig2 added in combination on neurite outgrowth from primary hippocampal neurones maintained on fibronectin.

5 Fig. 16 shows the effect of C3d in the indicated concentrations in μ M on proliferation of primary hippocampal neurones measured as incorporation of BrdU as described in example 8.

10 Fig. 17 shows the predicted amino acid sequence of human NCAM, 140 KD isoform precursor (SWISS-PROT: locus NCA1-HUMAN, accession no. P13591).

DETAILED DESCRIPTION OF THE INVENTION

15 In the nervous system, the ability to remodel connections between nerve cells is of major importance in the regeneration and well as in learning. Therefore, it is of considerable interest to identify substances that promote 20 such processes. Much effort has been concentrated on identifying substances that stimulate neuronal survival and neuritic outgrowth in vitro as such substances will be expected to possess a potential to stimulate regeneration and learning. The neural cell adhesion 25 molecule (NCAM) is believed to be important for the development and remodelling of neuronal connections and it is therefore of interest to identify ligands capable of stimulating NCAM-functions. It has previously been shown that antibodies against the Ig3 domain of NCAM can 30 stimulate neurite outgrowth.

The present invention is based on the surprising finding that the NCAM Ig2 domain strongly stimulates the outgrowth of neurites from NCAM presenting cells. Thus, 35 it has been found that NCAM Ig2 is a ligand of the NCAM Ig1 domain. It has further been found that the NCAM Ig2

domain stimulates neurite outgrowth by activation of specific signal transduction pathways. The inventors have also identified small peptides which stimulate neurite outgrowth. Active peptides selected from a peptide library have been identified, and a putative motif comprising two or more basic amino acid residues has been identified. The peptides have been shown to stimulate the same specific signal transduction pathways as the NCAM Ig2 domain. The results show that ligands of NCAM Ig1, 5 either the NCAM Ig2 domain or small functional mimics hereof, which are capable of activating specific signalling pathways, can promote neurite outgrowth and thereby be of benefit in regeneration and learning. Other functional mimics of the NCAM Ig2 domain, such as 10 antibodies and non-peptide molecules may be beneficial in the same way. Therefore, the present invention provides compounds and compositions which are or comprise small peptides, polypeptides, antibodies and non-peptide molecules recognising the NCAM Ig1 domain. When applied 15 to tissue containing NCAM-expressing cells these compounds and compositions will promote NCAM function. The compounds and the compositions can be applied to promote functions of the nervous system, the muscles and 20 any other NCAM-expressing tissues, including various 25 organs.

In its broadest aspect, the present invention relates to compounds which bind to the NCAM Ig1 domain and are capable of stimulating neurite outgrowth from and/or 30 proliferation of NCAM presenting cells. Such compounds may be a peptide or PNA sequence constituting the NCAM Ig2 domain, a fragment thereof or a mimic thereof.

In the present context, a mimic of the Ig2 domain should 35 be understood to be any compound which binds to the NCAM Ig1 domain and through said binding stimulates neurite

outgrowth from and/or proliferation of NCAM presenting cells. Mimics may be peptides, peptide derivatives, antibodies and non-peptide compounds such as small organic compounds, sugars and fats, as well as 5 peptidomimetics.

In accordance with the present invention, novel compounds are provided, which promote extension of neurites in the central and peripheral nervous system. Surprisingly, it 10 has been found that the compounds of the invention are able to promote formation and plasticity of neural connections.

22 peptides which were able to bind to recombinant, 15 labelled neural cell adhesion compound Ig1 (NCAM Ig1) in vitro have been identified from a peptide library.


The 22 sequences are ASKKPKRNIKA (SEQ ID NO:1), AKKERQRKDQT (SEQ ID NO:2), ARALNNGAKPK (SEQ ID NO:3), 20 AGSAVKKKKKA (SEQ ID NO:4), AKYVLIPIRIS (SEQ ID NO:5), ASTKRSMQGI (SEQ ID NO:6), ARRAILM(Q/T/N)-AL (SEQ ID NO:7), AYYLIVRVNRI (SEQ ID NO:8), ATNKKTGRRPR (SEQ ID NO:9), AKRNGPLINRI (SEQ ID NO:10), AKRSVQKLDGQ (SEQ ID NO:11), ARQKTMKPRRS (SEQ ID NO:12), AGDYNPDLDL (SEQ ID NO:13), ARKTRERKSKD (SEQ ID NO:14), ASQAKRRKGPR (SEQ ID NO:15), APKLDRLMLTKK (SEQ ID NO:16), AKKEKPNKPND (SEQ ID NO:17), AQMGRQSIDRN (SEQ ID NO:18), AEGGKKKKMRA (SEQ ID NO:19), AKKKEQKQRNA (SEQ ID NO:20), AKSRKGNSSLM (SEQ ID NO:21), ARKSRDMDTAIK (SEQ ID NO:22). 30

Three peptides, C3 (SEQ ID NO:1), D3 (SEQ ID NO:2) and D4 (SEQ ID NO:3) (Fig. 4) were further investigated for their ability to bind the NCAM Ig1 domain using plasmon surface resonance analysis and selected according to 35 their ability to inhibit aggregation of neurones and stimulate neurite outgrowth. By sequence analysis of

these peptides and scrambled peptides, a motif for binding to NCAM Ig1 could surprisingly be identified. The motif includes positively charged amino acids in a relatively loose sequence-order, K/R (aa)₀₋₈ K/R, 5 preferably K/R (aa)₀₋₁ K/R, wherein K and R designate lysine and arginine respectively and the positively charged amino acids are separated by up to 8 amino acid (aa) residues. Preferably, however, the positively charged amino acids are adjacent or separated by only one 10 amino acid residue.

Analysis of the active peptides isolated from the peptide library suggests that the motif may comprise more than 15 two positively charged amino acids, for example three or four basic amino acids.

Preferred peptides comprise the sequence:



20 wherein Xaa⁺ is a basic amino acid residue,
Xaa¹ is any amino acid residue,
Xaa is any amino acid residue, and
m, n, p, q and r independently are 0 or 1.

25 and wherein the basic amino acid residues preferably are lysine or arginine and r preferably is 1.

30 The nature of the amino acid residues Xaa and Xaa¹ does not seem to be important. It appears that they may be any amino acid residue. However, Xaa¹ is preferably proline (P) or glutamic acid (E).

35 In even more preferred peptides r is 1 and at least one of m and n is 1.

Preferred peptides of the invention comprise the sequence (K/R)0-1-K/R-X-K/R, wherein X has the meaning of Xaa¹, suitably the sequence K/R-K/R-X-K/R or K/R-X-K/R, more 5 suitably the sequence K/R-P-K/R, K/R-K/R-P-K/R, K/R-K/R-E-K/R or K/R-K/R-E-K/R and most suitably K-P-K, K-K-P-K, K-K-E-K or K-K-E-R. Examples are the sequences A-S-K-K-P-K-R-N-I-K-A (SEQ ID NO:1), A-K-K-E-R-Q-R-K-D-T-Q (SEQ ID NO:2), and A-R-A-L-N-W-G-A-K-P-K (SEQ ID NO:3).

10

According to the invention, peptides comprising the above sequence may be a part (hereinafter called a fragment) of the NCAM Ig2 domain or a mimic of the NCAM Ig2 domain. Furthermore, the peptides may bind to the Ig2 binding 15 site of the Ig1 domain or to a different binding site on the Ig1 domain. If the binding site is not the normal Ig2 binding site, the binding will mimic the normal binding and result in neurite outgrowth and/or proliferation of NCAM presenting cells in the same way.

20

It is clear that the peptides of the invention are not limited to the decapeptides identified and selected from the synthetic peptide library. These peptides only served as tools for identifying a motif in peptide ligands 25 expected to bind to the NCAM Ig1 domain.

The peptides may be modified, for example by substitution of one or more of the amino acid residues. Both L-amino acids and D-amino acids may be used. Other modification 30 may comprise derivatives such as esters, sugars, etc. Examples are methyl and acetyl esters. Polymerisation such as repetitive sequences or attachment to various carriers well-known in the art, e.g. lysine backbones or protein moieties such as bovine serum albumin (BSA) is 35 also an aspect of the invention.

The invention also concerns non-peptide mimics of the NCAM Ig2 domain or the peptides defined above. In the present context, such mimics should be understood to be compounds which bind to or in other ways interact with 5 the NCAM Ig1 domain and thereby stimulate neurite outgrowth from and/or proliferation of NCAM presenting cells.

In a further aspect, the present invention relates to 10 compounds which are anti-NCAM Ig1 antibodies. The antibodies may be monoclonal or polyclonal. Recombinant antibodies such as chimeric and/or humanised antibodies are also a part of the invention.

15 In a further aspect, the present invention relates to the NCAM Ig2 polypeptide, a fragment or a mimic thereof for use in the treatment of a normal, degenerated or damaged NCAM presenting cells. The treatment is a treatment of diseases and conditions of the central and peripheral 20 nervous system, of the muscles or of various organs. Only NCAM presenting cells may respond to such a treatment.

The invention also relates to a pharmaceutical 25 composition and a medicament comprising one or more of the compounds defined above.

In yet a further aspect, the present invention relates to methods of treating normal, degenerated or damaged NCAM 30 presenting cells *in vitro* or *in vivo*, the method involving administering an effective amount of one or more compounds as defined above.

The treatment comprises treatment of diseases or 35 conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers,

postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; of diseases and conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; and treatment of diseases and conditions of the organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidneys such as nephrosis and of the heart, liver and bowel.

15 Another aspect of the invention is the use of the compounds according to the invention in combination with a prosthetic nerve guide.

20 Yet another aspect of the invention is the use of the compounds according to the invention in the stimulation of the ability to learn and/or of the memory.

25 To be able to identify candidate ligands capable of stimulating NCAM function, the inventors have established a simple culture system (aggregate cultures) that permits a quantitative evaluation of the effect of various ligands. Hippocampal cells are provided from rat embryos. The cells are grown in a defined medium and dissociated cells are seeded in microtiter plates. After 24 h, the 30 amount of aggregates are counted. Compounds to be tested are added to the cell suspension immediately before seeding of cells in the microwells. When NCAM Ig1 binding ligands are present during the aggregation of cells, smaller, but more numerous cell aggregates are seen when 35 quantified 24 h after seeding of cells. The inhibiting effect of the ligands results in a blockage of the

formation of large aggregates from many small aggregates as the adhesion properties of NCAM are blocked. Thus small, but more numerous cell aggregates are seen in the presence of active ligands.

5

The system allows the examination of cell adhesion, cell migration and formation of processes in the treated cells leading to possibly neurite outgrowth. To investigate the latter further, neurite extension from single neurones 10 may be studied. Cells are prepared as in the aggregation study and seeded on a substrate of plastic or fibronectin. The cells are then maintained for a suitable time, whereafter the neurite outgrowth is analysed by a measurement of the neurite extension, for example by a 15 computer-assisted image analysis program. The mean length of the longest neurite of each cell was measured for neurites longer than 10 μM (see Figure 2). In addition, the mean number of branchpoints per neurite and the mean number of neurites per cell were determined. NCAM Ig1 20 ligands to be tested are added immediately before seeding the cells.

25

To investigate the mechanisms of the neuritogene effect, one of the ligands, C3 (SEQ ID NO:1) was added in combination with various compounds known to inhibit NCAM dependent signalling. The following compounds were found 30 to inhibit the stimulatory effect of C3 on neurite extension: verapamil (a inhibitor of L-type voltage dependent calcium channels), omega-conotoxin GVIA (co inhibitor of N-type voltage dependent calcium channels), pertussis toxin (pertussis inhibitor of certain G-proteins), an erbstatin analogue (erb; inhibitor of certain tyrosine kinases), antibody to an acidbox epitope in fibroblast growth factor receptors (FGF-Rs) (inhibitor 35 of NCAM-FGF-R binding and signalling), a peptide

corresponding to the so-called CAM homology domain (CHD) (inhibitor of NCAM-FGF-R binding and signalling).

5 In addition, the neuritogenic effect of C3 was completely abrogated by the NCAM Ig1 domain in solution. These results show that the ligands such as C3 stimulate neurite outgrowth by binding to the NCAM Ig1 domain and thereby activating signalling pathways in the neurone that are sensitive to the above mentioned inhibitor-
10 compounds.

15 The endogenous ligand of NCAM Ig1, NCAM Ig2 was tested for its effect on neurite outgrowth from primary hippocampal neurones maintained on a substrate of fibronectin. NCAM Ig2 was added to the culture-wells immediately before seeding of cells. It is found that NCAM Ig2 stimulates neurite outgrowth similar to the C3 peptide. The maximal neuritogenic effect of NCAM Ig2 was found at the same concentration at which the C3 peptide
20 had its maximal neuritogenic effect.

25 When the NCAM Ig2 domain was tested in combination with compounds known to inhibit NCAM dependent signalling as described for C3 above, the neuritogenic effect was inhibited in the same way. It thus appears that the endogenous ligand NCAM Ig2 and the artificial ligand C3 both bind to NCAM Ig1 and that both NCAM Ig2 and C3 stimulate neurite extension, which is believed to be due to activation of identical signal transduction pathways.

30 NCAM Ig2 and C3 were also tested for their effect on neurite outgrowth when added in combination. The effects were found to be non-additive. The results further indicate that NCAM Ig2 and C3 stimulate neurite extension
35 by identical mechanisms. They both bind to the NCAM Ig1

domain and thereby activate identical signalling pathways leading to neurite outgrowth.

Putative artificial ligands may be selected and 5 identified from peptide or non-peptide libraries. Any peptide library may be used. Synthetic peptide libraries as well as libraries containing fragmented natural occurring proteins, may be used in the search for useful peptides. Any kind of libraries comprising non-peptide 10 compounds may similarly be used.

Peptides are short molecules consisting of amino acids in a linear sequence. Amino acids are the building blocks of naturally occurring proteins which consist of long folded 15 chains of amino acids. Thus, peptides characterised by a certain sequence of amino acids may mimic a certain area of a protein. Naturally occurring proteins consist of L-amino acid residues. However, artificial peptides may also consist of or comprise D-amino acid residues. By 20 combinatorial chemistry, mixtures of beads carrying peptides of equal length can be constructed, in which each bead carries peptides of a unique sequence (Lam et al., 1991). Such a mixture of peptides on beads is called a peptide library.

25 In the present invention, peptides were identified by screening synthetic random peptide libraries comprising resin-bound decapeptides with purified recombinant NCAM Ig1. The synthesis of the resin-bound one-bead one-peptide 30 library was performed using the portioning, mix procedure (Furka, Å., Sebestyén, F., Asgedom, M. And Dibő, G. (1991) Int. J. Pep. Prot. Res. 37, 487-493). Polyethylene syringes served as reaction vessels throughout the synthesis. Screenings were done by incubating the resin with 35 biotinylated NCAM Ig1. Subsequently the resin was incubated with avidin-alkaline phosphatase. The substrates BCIP/NBT

(Sigma) were added as described by the procedure by Lam et al. (1992) and stained beads removed for micro sequencing.

5 The most intensely stained beads were selected under stereo microscope and sequenced on an ABI 470A equipped with an ABI 120A HPLC. 22 NCAM Ig1 binding peptide sequences were identified (FIG. 4(A); SEQ ID NO:1 to SEQ ID NO:22).

10 It is to be understood that the method chosen for identification and selection of interesting peptides is not critical for the identification a putative motif.

15 Peptide sequences to be synthesised were chosen by aligning the obtained sequences and examining these for repeated patterns revealing putative motifs (FIG 4(B)-(D)).

20 The three peptides called C3, D3 and D4 (FIG 4(B)-(D)) were synthesised and their binding to the NCAM Ig1 domain evaluated by plasmon surface resonance analysis. When immobilised on a sensor chip, peptide dendrimers (4 peptides linked to a lysine backbone (Fig. 2(C)) were used in order to secure an exposure of at least one peptide for binding to NCAM Ig 1 in solution. All three peptides bound the NCAM-Ig1 in solution. The three peptides were further 25 tested for their effect on neurite outgrowth. All three peptides strongly stimulated neurite outgrowth. Moreover, the peptides inhibited aggregation of cells.

30 To investigate which properties of the peptides are important for the effect, various control-peptides of the C3-sequence were constructed and tested.

35 To investigate the role of the individual residues in the C3-sequence, so-called scrambled peptides, comprising the same residues as C3 but in a different sequence, were constructed (121, 114 and C3scr in Fig. 7). Similarly,

scrambled peptides corresponding to the residues in the D3 and D4 sequences were constructed (scrambled D3 and scrambled D4 in Fig. 7). Furthermore, peptides containing the C3-sequence in which basic amino acids (Ks and Rs) 5 were substituted with alanines were constructed (116 - 119 in Fig. 7) to explore the role of these particular amino acids. Likewise, a peptide corresponding to the C3-sequence in which the proline-residue (Xaa^1) was substituted with an alanine was constructed, as prolines 10 are generally considered important for the structure of peptides. Substituting the proline with an alanine does not change the effect. Likewise, one basic amino acid could be alanine substituted without a change in effect. In contrast, peptides with two to four alanine 15 substitutions of the basic residues had no effect on aggregation indicating that these residues are important for the effect of C3. To further investigate the role of the basic amino acid residues in C3, a peptide containing the C3-sequence in which the basic amino acids were 20 modified by acetylation was constructed. The acetylation removes the charges from these residues while preserving the ability to form hydrogen bonds. A peptide in which four basic amino acids were modified by acetylation (C3dacetyl. K(120) in Fig. 7) inhibited aggregation as C3 25 indicating that not only the charges but also other properties of the basic amino acids such as the ability to form hydrogen bonds must be important for the effect of C3. Similar aggregate cultures were prepared in the presence of C3 as monomer, dendrimer (C3d) or as BSA-coupled 30 20-mer. Different forms of the C3 peptide were tested. It was found that monomeric, dendrimeric and BSA-coupled forms of C3 have similar effects on aggregation. The dendrimer of the C3 sequence is the most potent form, 35 presumably due to the ability to link several of the receptor domains. To verify that the receptor is in fact the NCAM Ig1 domain, the cells were incubated with this

domain prepared in *Pichia pastoris* in solution as described in Example 1. The presence of the NCAM Ig1 domain abrogated the effect of C3 demonstrating an interference with NCAM-mediated cell adhesion of C3. 5 These experiments show that the here identified NCAM Ig1 binding peptides influence NCAM mediated cell adhesion and thereby increase the number of cell aggregates and neuronal processes formed in cultures of primary neurones grown at high densities.

10 The substitution of only two basic amino acids in the sequence of the C3 peptide completely abolished the neuritogenic effect. Thus, when two to four lysines and arginines in the sequence were substituted by alanines, 15 the neurite stimulatory effect was completely abrogated. This shows that the basic amino acids in the C3 sequence are crucial for its effect. Surprisingly, peptides in which the same amino acids were modified by acetylation have some effect on cell adhesion and neurite outgrowth, 20 although not to the same extent as the intact C3 peptide, showing that not only the charges but also other properties of the basic amino acids, such as the ability to form hydrogen bonds, are of importance. In addition, the effect of the intact peptide can be blocked by 25 equimolar concentrations of the NCAM Ig1 domain in solution. This shows that the peptide works by binding to the NCAM Ig1 domain expressed by neurones.

30 The effect of the ligands on proliferation and cell growth was also tested. The C3 peptide was found to initially stimulate proliferation and cell growth. After this initial promotion of proliferation, the peptides stimulate differentiation by increasing neurite outgrowth and at the same time suppressing proliferation. Thus the 35 net effect on proliferation depends on the growth status of the cells. An effect on proliferation has been shown

for primary cell cultures from the hippocampus cells and cultures of rat pheochromocytoma cell line PC12 cells. Accordingly, the ligands stimulate neurite outgrowth from and/or proliferation of NCAM presenting cells.

5


In particular, the compound of the invention may be a peptide which binds to the NCAM Ig1 domain through a binding motif which comprises at least 2 basic amino acid residues. Peptides comprising at least 2 basic amino acid residues within a sequence of 10 amino acid residues, 10 suitably within a sequence of 3 amino acid residues, are believed to be very interesting compounds for the purpose of the present invention.

15

The analysis of the isolated peptide ligands revealed that the ligands may advantageously comprise more than two basic amino acids.

20

In accordance herewith, interesting peptides comprise the sequence



wherein

25

Xaa^+ is a basic amino acid residue,

Xaa^1 is any amino acid residue,

Xaa is any amino acid residue, and

m, n, p, q and r independently are 0 or 1.

30

The basic amino acid residues are preferably selected from lysine (K) and arginine (R) and r is preferably 1.

35

The nature of the amino acid residues Xaa and Xaa^1 does not seem to be important. It appears that they may be any amino acid residue. However, Xaa^1 is preferably proline (P) or glutamic acid (E).

In even more preferred peptides r is 1 and at least one of m and n is 1.

5 Preferred peptides of the invention comprise the sequence $(K/R)0-1-K/R-X-K/R$, wherein X has the meaning Xaa^1 , suitably the sequence $K/R-K/R-X-K/R$ or $K/R-X-K/R$, more suitably the sequence $K/R-P-K/R$, $K/R-K/R-P-K/R$, $K/R-K/R-E-K/R$ or $K/R-K/R-E-K/R$, even more suitable $K-P-K$, $K-K-P-K$, $K-K-E-K$ or $K-K-E-R$ and most suitable the sequences $A-S-K-K-P-K-R-N-I-K-A$ (SEQ ID NO:1), $A-K-K-E-R-Q-R-K-D-T-Q$ (SEQ ID NO:2), or $A-R-A-L-N-W-G-A-K-P-K$ (SEQ ID NO:3).

15 It may be speculated that the reason why the distance between the basic amino acid residues is a variable factor in the deduced motif, is that one of the important properties of the ligand may be the exposure of a cluster of basic amino acid residues, i.e. an epitope comprising basic amino acids residues. Such a cluster may be created 20 by a sequence of closely linked basic amino acids or alternatively through peptide/protein folding. Advantageously, the basic amino acid residues may be exposed on the surface of a carrier. Particularly, multimeric peptides such as dendrimers may form 25 conformational determinants or clusters due to the presence of multiple flexible peptide monomers.

As discussed above, the analysis of the active peptides isolated from the peptide library suggests that the motif 30 may comprise more than two positively charged amino acids, for example three or four basic amino acids. The strength of the binding and of the resulting downstream signal probably depend upon the number and/or the position of the basic amino acids in the peptide, 35 resulting in clusters of variable functional strength. The position of other amino acids in the peptide may be

of importance, especially in the case of peptide folding. The variable strength of the cluster may result in variable binding constants and thus in variable strength in signalling.

5

Without wishing to be bound by a certain theory, the inventors believe that active ligands to the NCAM Ig1 domain are ligands which bind to the NCAM Ig1 domain and thus trigger a conformational change of the domain 10 resulting in a signalling cascade being initiated, which signalling influences proliferation of cells and/or neurite outgrowth. Thus, a suitable ligand may be any compound which can trigger a conformational change of the NCAM Ig1 domain, resulting in a downstream signalling.

15

Very interesting peptides are those which correspond to a part of the NCAM Ig2 domain, are a mimic or fragment of the NCAM Ig2 domain.

20

The peptides may bind to the Ig2 binding site on the NCAM Ig1 domain or to a binding site different from the NCAM Ig2 binding site. It is believed that the ligands C3, D3 and D4 bind to a site different from the binding site of NCAM Ig2 or fragments thereof.

25

Other compounds which are interesting compounds for the purposes of the present invention are non-peptide molecules mimicking the binding of the NCAM Ig2 domain or the artificial ligands. Such other compounds may be 30 selected from small organic compounds, sugars and lipids, as well as peptidomimetics, peptoides and peptomers.

Libraries of small organic compounds may be screened to identify artificial ligands of the NCAM Ig1 domain, which 35 ligands may stimulate NCAM activity. Such libraries or their construction are commonly known and the screening

for useful ligands may follow the methods for screening disclosed in this paper, or in ways obvious to the skilled person.

5 Such other compound may also be an anti-NCAM Ig1 antibody (monoclonal, polyclonal or recombinant), which antibody further may be chimeric or humanised. The production of polyclonal as well as monoclonal anti-NCAM Ig1 antibodies may follow common known procedures. Mice or rabbits may
10 serve as the primary immunisation forum, in which antibodies to NCAM Ig1 are raised. Purified polyclonal antibodies may be used without any further treatment. Alternatively, monoclonal antibodies may be produced. Methods of producing monoclonal antibodies are common in
15 the art. Recombinant antibodies such as chimeric and humanised antibodies may also be obtained by methods common in the art. Possible active antibodies are then screened according to the methods disclosed above or in similar ways.

20 Substances with the potential to promote neurite outgrowth as well as survival and proliferation of neuronal cells such as certain endogenous trophic factors are prime targets in the search for compounds that
25 facilitate neuronal regeneration and other forms of neuronal plasticity (Fu and Gordon, 1997). Peripheral nerves possess a potential to regenerate and re-establish functional connections with their targets after various injuries. However, functional recovery is rarely complete
30 and peripheral nerve damage remains a considerable problem. In the central nervous system, the potential for regeneration is very limited. Therefore, the identification of substances with the ability to promote functional regeneration in the peripheral and the central nervous system is of great interest. To evaluate the potential of a substance to promote regeneration, the
35

ability to stimulate neurite outgrowth and proliferation and survival of neuronal cells may be investigated. The NCAM Ig1 binding compounds of the present invention are shown to promote neurite outgrowth and to affect neuronal 5 proliferation and are therefore most likely good promoters of regeneration of neuronal connections and thereby of functional recovery after damages as well as promoters of neuronal function in other conditions where such an effect is required.

10 Accordingly, the present invention relates to the NCAM Ig2 domain, a fragment or a mimic thereof for use in the treatment of a normal, degenerated or damaged NCAM presenting cell. In particular, the invention relates to 15 the NCAM Ig2 domain, a fragment or a mimic thereof for use in the treatment of normal, degenerated or damaged NCAM presenting cells, which treatment consists of stimulating outgrowth from and/or proliferation of the NCAM presenting cells.

20 The treatment may suitably be a treatment of diseases and conditions of the central and peripheral nervous system, of the muscles or of various organs such as 25 treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibres, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, 30 dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia,

treatment of diseases of muscles including conditions with impaired function of neuro-muscular connections such as genetic or traumatic atrophic muscle disorders,

- 5 a treatment of diseases of various organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart, liver and bowel, and
- 10 treatment or stimulation of the ability to learn and/or of the memory.

The present invention also relates to the use of the NCAM Ig2 domain, or a fragment of mimic thereof in the manufacture of a medicament for the treatment of normal, degenerated or damaged NCAM presenting cells. Thus, the present invention relates to the use of the NCAM Ig2 domain, or a fragment of mimic thereof in the manufacture of a medicament for the treatment of NCAM presenting cells, so as to provide a stimulation of neurite outgrowth from and/or proliferation of NCAM presenting cells.

In particular, the use of the NCAM Ig2 domain, or a fragment or mimic thereof in the manufacture of a medicament for the treatment of NCAM presenting cells, wherein the medicament is for treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibres, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; for treatment of diseases or conditions of

the muscles including conditions with impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; or for treatment of diseases or conditions of various organs, such as 5 degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart, or is for the stimulation of the ability to learn and/or of the memory.

10 The invention also relates to a pharmaceutical composition comprising one or more of the compounds as defined above. In particular, the composition of the invention may comprise a compound being the NCAM Ig2 polypeptide, a fragment or a peptide mimic thereof. In a 15 preferred embodiment, the peptides are formulated as multimers, e.g. bound to carriers. The peptides may suitably be formulated as dendrimers such as four peptides linked to a lysine backbone, or coupled to a polymer carrier, for example a protein carrier, such as 20 BSA. Such formulations are well-known to the person skilled in the art.

25 The invention also concerns a method of treating normal, degenerated or damaged NCAM presenting cells *in vitro* or *in vivo*, which method involves administering, *in vitro* or *in vivo*, an effective amount of one or more of the compounds described above or a composition as described above, so as to provide a stimulation of neurite outgrowth from and/or proliferation of NCAM presenting 30 cells.

35 In the method of the present invention, the treatment is preferably an *in vivo* treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibres, postischaemic, e.g.

resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; of diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; or of diseases or conditions of the organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart. to the central or peripheral nervous system of a patient in need of treatment, and the method is characterised in that an effective amount of one or more of the compounds or a composition as defined above is administered to said patient.

Furthermore, the method of the invention may also be such, wherein the treatment leads to regeneration of nerves. The compounds are in particular used in combination with a prosthetic device such as a prosthetic nerve guide. Thus, in a further aspect, the present invention relates to a prosthetic nerve guide, characterised in that it comprises one or more of the compounds or the composition defined above. Nerve guides are known in the art.

In a further aspect, the invention relates to a method of stimulating the ability to learn and/or the memory in a subject, which method involves administering to a subject in need thereof an effective amount of one or more of the compounds as defined above or a composition as defined above.

The invention further concerns a medicament for the treatment of diseases and conditions of the central and peripheral nervous system, of the muscles or of various organs, which medicament comprises an effective amount of 5 one or more of the compounds as defined above or a composition as defined above in combination with pharmaceutically acceptable additives. Such method may suitably be formulated for oral, percutaneous, intramuscular, intracranial, intranasal or pulmonal 10 administration.

In yet another embodiment, the present invention relates to a composition for use in the stimulation of learning and/or memory in a subject, which the composition 15 comprises an effective amount of one or more of the compounds defined above or a composition as defined above in combination with one or more pharmaceutically acceptable additives. Such composition may suitably be formulated for oral, percutaneous, intramuscular, 20 intracranial, intranasal or pulmonal administration.

As appears from the above, increased plasticity is believed to be beneficial in the nervous system such as learning and regeneration and in other conditions outside the nervous system involving degenerative NCAM function. 25 The effect of peptides of the present invention were investigated with respect to regeneration, i.e. axonal outgrowth from isolated superior cervical ganglia. It was found that peptide of the above-identified motif 30 stimulated outgrowth as compared to a control peptide. It seems as if the observed effect is largely influenced by the dose administered, which presumably is due to the activating of signal transduction pathways by the NCAM Ig1 binding compounds resulting in a bell-shaped dose- 35 response curve for neurite outgrowth (Fig 8 and 13). Thus a similar bell-shaped dose-response curve will be

expected for the effect of NCAM Ig1 binding compounds on neuronal regeneration and other forms of plasticity dependent on activation of NCAM-mediated signal transduction pathways. The effect of NCAM Ig1 binding compounds on learning could be investigated *in vivo* by intraventricular infusion of the compounds in rodents or other animals followed by examination of the learning abilities of the animals after injections of various doses of NCAM Ig1 binding compounds. Injections should be performed before or at various time points after training as an inhibitory effect of NCAM-antibodies on certain forms of learning has been demonstrated when such injections were performed 5 to 8 hours following training (Scholey et al 1993). Useful learning models for evaluation of the effect of NCAM Ig1 binding compounds on learning include passive avoidance and water maze learning in rodents or chicken. The effect of NCAM Ig1 binding compounds on synaptic plasticity associated with learning could be investigated *in vitro* or *in vivo* by measuring the induction or maintenance of long-term potentiation after application of NCAM Ig1 binding compounds, as has been done for NCAM-antibodies (Rønn et al 1995).

Surprisingly, it was found that NCAM Ig1-binding peptide ligands displaying a motif as indicated above stimulate NCAM mediated signalling. In particular, the C3 peptide stimulates NCAM functions including neurite extension by interacting with the NCAM Ig1 domain, thereby inducing signal transduction.

Accordingly, the compounds of the present invention are believed to have a beneficial effect in conditions, where which NCAM functions have been shown to be of importance.

As mentioned above, NCAM has been found to be expressed in several tissues and organs. Thus, interference with NCAM transmembrane signalling may have a beneficial influence in diseases and disorders such as

- 5 1) Diseases and conditions of the central and peripheral nervous system, in which increased potential for regeneration and synaptic plasticity is desirable such as
- 10 postoperative nerve-damage; traumatic nerve damage; disorders characterised by impaired myelination of fibers; postischaemic damage, e.g. resulting from a stroke; Parkinsons disease; Alzheimers disease; other dementias including multiinfarct dementia; Sclerosis; 15 nerve degeneration associated with diabetes mellitus; disorders affecting the circadian clock; disorders affecting neuro-muscular transmission; and Schizophrenia;
- 20 2) Diseases of the muscles including conditions with impaired function of neuro-muscular connections such as genetic atrophic muscle disorders; and traumatic atrophic muscle disorders;
- 25 3) Degenerative conditions of various organs such as degenerative conditions of the gonads; degenerative conditions of the pancreas including disorders involving β -cells; diabetes mellitus type I and II; degenerative conditions of the kidneys such as nephrosis; and degenerative conditions of the heart, liver and bowel.
- 30 As mentioned above, the present invention also relates to medicaments and compositions. Strategies in formulation 35 development of medicaments and compositions based on the compounds of the present invention generally correspond to formulation strategies for any other protein-based drug product. Potential problems and the guidance

required to overcome these problems are dealt with in several textbooks, e.g. Therapeutic Peptides and Protein Formulation. Processing and Delivery Systems, Ed. A.K. Banga, Technomic Publishing AG, Basel, 1995.

5

Injectables are usually prepared either as liquid solutions or suspensions, solid forms suitable for solution in, or suspension in, liquid prior to injection. The preparation may also be emulsified. The active 10 ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like, and combinations thereof. In addition, if desired, the 15 preparation may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or which enhance the effectiveness or transportation of the preparation.

20

Formulations of the compounds of the invention can be prepared by techniques known to the person skilled in the art. The formulations may contain pharmaceutically acceptable carriers and excipients including micropheres, liposomes, microcapsules, nanoparticles or the like.

25

The preparation may suitably be administered by injection, optionally at the site, where the active ingredient is to exert its effect. Additional formulations which are suitable for other modes of 30 administration include suppositories, nasal, pulmonal and, in some cases, oral formulations. For suppositories, traditional binders and carriers include polyalkylene glycols or triglycerides. Such suppositories may be formed from mixtures containing the active ingredient(s) 35 in the range of from 0.5% to 10%, preferably 1-2%. Oral formulations include such normally employed excipients

as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, 5 tablets, pills, capsules, sustained release formulations or powders and generally contain 10-95% of the active ingredient(s), preferably 25-70%.

Other formulations are such suitable for nasal and 10 pulmonal administration, e.g. inhalators and aerosols.

The active compound may be formulated as neutral or salt forms. Pharmaceutically acceptable salts include acid 15 addition salts (formed with the free amino groups of the peptide compound) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic acid, oxalic acid, tartaric acid, mandelic acid, and the like. Salts formed with the free carboxyl group may also be derived from 20 inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

25 The preparations are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective. The quantity to be administered depends on the subject to be treated, including, e.g. the weight and age of the subject, the 30 disease to be treated and the stage of disease. Suitable dosage ranges are of the order of several hundred μ g active ingredient per administration with a preferred range of from about 0.1 μ g to 1000 μ g, such as in the range of from about 1 μ g to 300 μ g, and especially in the 35 range of from about 10 μ g to 50 μ g. Administration may be performed once or may be followed by subsequently

administrations. The dosage will also depend on the route of administration and will vary with the age and weight of the subject to be treated.

5 Some of the compounds of the present invention are sufficiently active, but for some of the others, the effect will be enhanced if the preparation further comprises pharmaceutically acceptable additives and/or carriers. Such additives and carriers will be known in
10 the art. In some cases, it will be advantageous to include a compound, which promote delivery of the active substance to its target.

15 In many instances, it will be necessary to administrate the formulation multiple times. Administration may be a continuous infusion, such as intraventricular infusion or administration in more doses such as more times a day, daily, more times a week, weekly, etc. In connection with the use in nerve guides, the administration may be
20 continuous or in small portions based upon controlled release of the active compound(s). Furthermore, precursors may be used to control the rate of release and/or site of release. Other kinds of implants and well as oral administration may similarly be based upon
25 controlled release and/or the use of precursors.

30 The treatment needs not be a treatment of an diagnosed disease, but may alternatively be a prophylactic treatment of subjects in general or of subjects known to have a high risk of getting one of the disease discussed above.

The invention is further illustrated by the non-limiting examples.

35

EXAMPLES

EXAMPLE 1

Preparation of the receptor Ig domain 1 of NCAM

5 The Ig1 domain of NCAM was produced as a recombinant protein in *Pichia pastoris*. The cDNA fragment encoding amino acids 1-97 of rat NCAM was synthesised by PCR and amplified cDNA was subcloned into an *Xho* I/*Bam* HI site of the *pHIL-S1* plasmid (Invitrogen Corporation, San Diego, USA). An *E. coli* strain *Top 10 F* (Invitrogen Corporation, San Diego, USA) was used for transformation. The recombinant plasmid was linearised with *Nsi* I and used for transformation of *Pichia pastoris* strain *His 4 GS-115* (Invitrogen Corporation, San Diego, USA). Transformation and selection was performed according to a *Pichia* Expression Kit manual supplied by the manufacturer. The recombinant protein was designated as Ig1 PP (Ig-like domain 1 produced in *P. pastoris*). The authenticity of Ig1 PP was secured by amino acid sequencing and MALDI-MS confirming the expected molecular weight of 11 kD. Cells were grown essentially according to the *Pichia* Expression Kit manual. After induction supernatant from growing cells was filtered through a 0.21 mm filter, concentrated by ultrafiltration and purified by gel filtration using a 20 Sephadex G-50 column (Pharmacia Biotech AB, Sweden). 25

EXAMPLE 2

Preparation of the Ig domain 2 of NCAM

30 The cDNA encoding the Ig2 domain of NCAM was synthesised by PCR corresponding to residues 100 to 191. Rat NCAM-120 cDNA was used as template. The amplified cDNA fragment was subcloned into a *Sna* BI/*Avr* II site of the *pPIC9K* plasmid (Invitrogen). The recombinant plasmid was linearised with *Sac* I and used for transformation of 35 *Pichia pastoris* strain *His 4 GS-115* (Invitrogen)

according to the protocol supplied by the manufacturer. The recombinant Ig2 domain of NCAM was expressed after induction in a 2 litre fermentor (MBR Mini Bioreactor, MBR Bioreactor AG). Thereafter, the expression medium was 5 concentrated 10 times by ultra-filtration. The Ig2 domain was purified by gel-filtration by means of Sephadex G25 (Pharmacia) followed by ion exchange chromatography using a 5 ml HiTrap SP column (Pharmacia) yielding 10-15 mg per litre of expression medium. The authenticity of the NCAM 10 Ig2 domain was confirmed by amino acid sequencing and mass spectroscopy. In the N-terminal, the original residues Lys-1 and Leu-2 were replaced with Tyr-1 and Val-2 due to cloning site considerations.

15 EXAMPLE 3

Synthesis and screening of resin-bound decapeptide libraries

The synthesis of the resin-bound one-bead one-peptide 20 library was performed using the portioning, mix procedure (Furka, Å. et al., (1991) Int. J. Pep. Prot. Res. 37, 487-493). Polyethylene syringes served as reaction vessels throughout the synthesis and the final TFA-deprotection. TentaGel resin (Rapp Polymere, Tübingen, Germany) was 25 divided into 18 aliquots and the protein L-amino acids except cysteine and histidine were used. Side-chains were protected with the following protecting groups: Asp(tBu), Glu(tBu), Tyr(tBu), Ser(tBu), Thr(tBu), Asn(trt), Gln(trt), Lys(Boc), Trp(Boc), Arg(pmc). Fmoc-protected amino acids (5 30 eq; Milligen or Novabiochem) were coupled overnight using 5eq DIC and 5eq HOBT. Removal of the Fmoc group was accomplished with 25% piperidine in DMF for 20 min. The side chain protecting groups were removed with 82.5% TFA, 5% anisole, 5% H₂O, 5% EDT, 2.5% thioanisole at room 35 temperature for 2.5 h followed by washing with tetrahydrofuran and 1% HOAc and the resin was subsequently

lyophilised. Screenings were done by incubating 2 ml resin (equivalent to ca. 10^6 beads) with biotinylated receptor in Tris/HCl buffer (Tris/HCl 0.025 M, pH 7.2, 0.25 M NaCl, 0.1 % (w/v) Tween 20) containing 0.1% Gelatin (Sigma) for 60 min. Subsequently the resin was washed in Tris/HCl buffer and incubated with avidin-alkaline phosphatase (diluted 1:20000) for 30 min. The substrates BCIP/NBT (Sigma) were added as described by the procedure by Lam et al. (1992) and stained beads were removed for micro sequencing. The library was screened with the receptor NCAM Ig1-PP (10 mg/ml).

EXAMPLE 4

15 Sequencing of beads and selection of peptides to be synthesised

15 The most intensely stained beads were selected under stereo microscope and sequenced on an ABI 470A equipped with an ABI 120A HPLC. The 22 peptide sequences obtained (SEQ ID NO:1 to SEQ ID NO:22) are shown in Fig. 4A. A conspicuous finding was the high prevalence of the basic amino acids lysine (K) and arginine (R) in these identified NCAM Ig1 binding sequences. Peptide sequences to be synthesised and used in the further investigations were chosen by aligning 20 the obtained sequences and examining these for repeated patterns revealing putative motifs. Three apparent motifs were identified within the peptides. The first motif was the sequence K/R-K/R-P-K/R-K/R-N/S that was partially conserved in a group of peptides including the C3 peptide as shown in Fig. 4B. The second motif was K/R-K/R-E-K/R-X-K/R-K/R found partially conserved in three peptides 25 including D3 (Fig. 4C). The third motif, G-X-K/R-P-K/R, was found in two peptides including D4 (Fig. 4D).

35 EXAMPLE 5

Synthesis of peptides

Three peptides, C3 (SEQ ID NO:1), D3 (SEQ ID NO:2) and D4 (SEQ ID NO:3) were selected for further analysis and synthesised on TentaGel resin with Rink amide linker (p-((R,S)- α -(1-(9H-fluoren-9-yl)-methoxyformamido)-2,4-dimethoxybenzyl)-phenoxyacetic acid (Novabiochem)) using Fmoc-protected amino acids (3 eq.). Coupling was performed for >60 min. with TBTU (3 eq.), HOBt (3 eq.) and DIEA (4.5 eq.) in a manual multicolumn apparatus. Fmoc was deprotected with 20% piperidine in DMF for 10 min. Synthesis of peptide dendrimers was accomplished by coupling Fmoc-Lys(Fmoc)-OH (Novabiochem) to the linker resin followed by Fmoc-deprotection of the Fmoc group and further coupling of Fmoc-Lys(Fmoc)-OH was performed. After Fmoc-deprotection the synthesis of peptides was performed as above for the monomeric peptides. Peptidyl resins were deprotected with TFA 90%, 5% H₂O, 3% EDT, 2% thioanisole, precipitated in diethyl ether, washed three times in diethyl ether, solubilised in 5% AcOH and lyophilised. Amino acid analysis was performed using Waters picotag and Waters 501 pump connected to WISP 712. Waters 600E equipped with Waters 996 photodiode array detector was used for analytical and preparative HPLC on C₁₈ columns (Delta-Pak 100 \AA 15um, Millipore). MALDI-MS was done on a VG TOF Spec E, Fisions Instrument. The peptides were at least 95% pure as estimated by HPLC.

To investigate the role of the individual residues in the C3-sequence, so-called scrambled peptides, comprising the same residues as C3 but in a different sequence, were constructed in the same way (121, 114 and C3scr in Fig. 7). Similarly, scrambled peptides corresponding to the residues in the D3 and D4 sequences were constructed (scrambled D3 and scrambled D4 in Fig. 7). Furthermore, peptides containing the C3-sequence in which basic amino acids (Ks and Rs) were substituted with alanines were

constructed (116 - 119 in Fig. 7) to explore the role of these particular amino acids. Likewise, a peptide corresponding to the C3-sequence in which the proline-residue (Xaa^1) was substituted with an alanine was 5 constructed. To further investigate the role of the basic amino acid residues in C3, a peptide containing the C3-sequence in which the basic amino acids were modified by acetylation was constructed (C3dacetyl. K(120) in Fig. 7).

10

EXAMPLE 6

Plasmon Surface Resonance Analysis

Real-time biomolecular interaction analysis was performed 15 using a BIALite instrument (Pharmacia Biosensor AB, Sweden). All experiments were performed at 25°C using Hepes buffered saline (HBS: 10mM Hepes pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% v/v Surfactant P20 (Pharmacia Biosensor, Sweden) as running buffer. The flow rate was 5 ml/min. 20 Dendrimer peptides C3, D3 and D4 (four peptide-monomers coupled to a backbone consisting of three lysines) were immobilised on a sensor chip CM5 (Pharmacia Biosensor AB, Sweden) using the following procedure: the chip was activated by 10ml 0.05 M N-hydroxysuccinimide, 0.2 M N- 25 ethyl-N'-(dimethylaminopropyl)carbodiimide; peptides were immobilised using 35 ml peptide solution in HBS at a concentration of 60 µg/ml; finally the chip was blocked by 35 µl 1 M ethanalamine hydrochloride pH 8.5. Binding of Ig1 to dendrimer peptides: 50 ml of Ig1 or IgII at the indicated concentrations were applied. The chip was 30 regenerated by two 5 ml pulses of 5 mM NaOH. Two independent experiments were performed. The results confirmed that C3, D3 and D4 bind to the NCAM Ig1 domain.

35 EXAMPLE 7

Aggregation and neurite outgrowth

1) Influence of NCAM Ig1 binding compounds on NCAM mediated cell adhesion

5 Hippocampal cells were prepared from rat embryos gestational day 17-19. Cerebellar cells were prepared from postnatal day 4-7 mice. Cells were grown in a defined medium consisting of DMEM/F12 (Gibco, BRL) supplemented with N2 (Gibco, BRL) or Neurobasal supplemented with B27
10 (Gibco, BRL), in both cases supplemented with 20 mM HEPES (Gibco, BRL), 0,4% w/v bovine serum albumin (Sigma) and 100 iU/ml penicillin-streptomycin. Dissociated cells were seeded in 60 well microtiter plates (50.000 in 15 ml per well) essentially as described (Maar et al., 1995). After
15 24 h, the amount of aggregates were counted. Peptides to be tested were added to the cell suspension immediately before seeding of cells in the microwells. When the NCAM Ig1 binding peptides, C3, D3 and D4 were present during the aggregation of cells, a higher number of cell
20 aggregates resulted when quantified 24 h after seeding of cells. Fig. 5 shows the number of aggregates measured 24 h after seeding of cells in the presence of C3d in the indicated concentrations in μ M (concentration calculated with respect to the amount of peptide monomers present on
25 the peptide-dendrimers). The peptide moreover resulted in an increase in the number of neuronal processes formed (Fig. 6). D3- and D4-dendrimer likewise increased the number of aggregates formed after 24 h. Scrambled peptides based on the C3-sequence also inhibited aggregation. The effect of the various peptides tested is
30 shown in Fig 7. To localise the active residues of the C3-peptide, alanine substitutions were carried out. Substituting the proline with an alanine did not change the effect. Likewise, one basic amino acid could be substituted by alanine without a change in effect, thus
35 such a peptide (termed 116" in Fig. 7). In contrast,

peptides with two to four alanine substitutions of the basic residues had no effect on aggregation indicating that these basic residues are important for the effect of C3. Similar aggregate cultures were prepared in the presence of C3 as monomer, dendrimer or as BSA-coupled 5 20-mer. Different forms of the C3 peptide were tested. It was found that monomeric, dendrimeric and BSA-coupled forms of C3 had similar effects on aggregation. However, the dendrimer of the C3 sequence was the most potent 10 form, presumably due to the ability to link several of the receptor domains. To verify that the receptor was situated in the NCAM Ig1 domain, the cells were incubated with this domain prepared in *Pichia pastoris* as described in Example 1 in solution in a concentration of 5.4 or 54 15 μ g/ml. The presence of the NCAM Ig1 domain abrogated the effect of C3 demonstrating an interference with NCAM-mediated cell adhesion of C3. These experiments show that the here identified NCAM Ig1 binding peptides influence 20 NCAM mediated cell adhesion and thereby increase the number of cell aggregates and neuronal processes formed in cultures of primary neurones grown at high densities.

2) NCAM Ig1 binding compounds promote neurite outgrowth

25 Hippocampal cells were prepared from rat embryos gestational day 18. 5000 cells/well, corresponding to approximately 4000 cells/cm², were seeded in 8 well LabTek Tissue Culture Chamber Slides with a growth 30 surface of Permanox plastic (NUNC A/S, Denmark) or fibronectin (cocultures) and maintained for 20 h as described in Example 7 (1).

For cocultures, neurones were seeded on monolayers of 35 fibroblasts, either L-cells or 3T3 cells with or without NCAM-B expression. Neurones were visualised using immunohistochemical staining for growth associated protein

43 kD (GAP43). Briefly, cells were fixed 30 min in 4% paraformaldehyde in phosphate buffered saline (PBS). The primary antibody was rabbit anti-GAP43 1:100 in PBS with 1% fetal bovine serum(FBS), 0.1% bovine serum albumin (BSA),
5 50 mM glycine, 0.02% NaN₃, 2% saponine 1h at room temperature or overnight at 4°C. The second antibody was biotinylated swine-anti-rabbit immunoglobulins 1:100 in PBS with 1% BSA 1h at room temperature. The third layer was streptavidine coupled to FITC or horse radish peroxidase (HRP) 1:100 1h at room temperature. Between layers, washings were performed 3X20 min in PBS with 1% BSA. Images of living or stained neurones were captured and analysed by the image analysis program Line Length created at the Protein Laboratory. Putative axons were identified as the 10 longest neurite of each cell. Only neurites longer than 10 mm were considered.
15

Fig. 8 shows the effect of C3 added to cocultures of primary hippocampal neurones on monolayers of fibroblasts 20 stably expressing NCAM-140 (LBN) or monolayers of fibroblasts without NCAM expression (LVN). In this model, NCAM expressed by transfected fibroblasts induce an increased neurite outgrowth from neurones. The mean length of neurites on NCAM-expressing fibroblasts was longer than the mean length of neurites on fibroblasts 25 without NCAM expression. In the presence of C3, there was no difference between the length of neurites on fibroblasts with or without NCAM expression showing that C3 binds to NCAM (0.54 or 5.4 μ M) in both cerebellar and 30 hippocampal neurones. When neurones were maintained on fibroblasts without NCAM-expression, neurite extension was stimulated by C3 in similar concentrations when compared to controls maintained in the absence of C3. This shows that C3 stimulates neurite outgrowth.

To investigate the stimulatory effect on neurite extension, cells were prepared as described and seeded on a substrate of plastic or fibronectin. Cells were then maintained for 21 h and neurite outgrowth was analysed by computer-assisted image analysis using the program Linelength. The mean length of the longest neurite of each cell was measured for neurites longer than 10 μM . In addition, the mean number of branchpoints per neurite and the mean number of neurites per cell were determined.

5 NCAM Ig1 binding peptides C3, D3 and D4 were added immediately before seeding the cells. This resulted in an increase in neurite outgrowth. The results for the measurements of the longest neurite per cell are shown in Fig. 9 and Fig. 10 in which the concentrations are given in μM . A similar dose-response relationship was found when measuring the number of neurites per cell and the branching of neurites. Scrambled peptides with similar amino acid composition but altered sequences had similar effects as C3, D3 and D4. The effect on neurite outgrowth 10 of the tested NCAM Ig1 binding peptides and the various 15 control-peptides is shown in fig. 7.

20

To investigate which properties of the NCAM Ig1 binding peptides were important for the observed neuritogenic effect, peptides corresponding to the C3-sequence, but 25 having alanine substitutions of basic amino acids were tested for their effect on neurite outgrowth (Fig. 11). The length of the longest neurite, the number of neurites per cell and the branching of neurites was strongly 30 stimulated by the C3 peptide (0.54 μM). A peptide with a similar sequence apart from one alanine substitution of a basic amino acid had similar effects. In contrast, peptides with two to four alanine substitutions had no 35 effect. To investigate the mechanisms of this effect, the C3 peptide (0.54 μM) was added in combination with various compounds known to inhibit NCAM dependent

signalling (Fig. 12 and Fig. 13). The following compounds were found to inhibit the stimulatory effect of C3 on neurite extension: 10 μ M verapamil (ve inhibitor of L-type voltage dependent calcium channels), 0.27 μ M omega-conotoxin GVIA (co inhibitor of N-type voltage dependent calcium channels), 1 μ g/ml pertussis toxin (pertus inhibitor of certain G-proteins), an erbstatin analogue (erb 0.2 μ M. inhibitor of certain tyrosine kinases), antibody to an acidbox epitope in fibroblast 5 growth factor receptors (FGF-Rs) (1:200 inhibitor of NCAM-FGF-R binding and signalling), a peptide corresponding to the so-called CAM homology domain (CHD) (175 μ M, inhibitor of NCAM-FGF-R binding and signalling). In addition, the neuritogenic effect of C3 was completely 10 abrogated by the NCAM Ig1 domain, prepared as described in Example 1, in solution. These results show that C3 stimulates neurite outgrowth by binding to the NCAM Ig1 domain and thereby activating signalling pathways in the neurone that are sensitive to the above mentioned 15 inhibitor-compounds.

To investigate the endogenous ligand of NCAM Ig1, the NCAM Ig2 domain was prepared in *Pichia pastoris* (see Example 2) and tested for its effect on neurite outgrowth 20 from primary hippocampal neurones maintained on a substrate of fibronectin. The polypeptide comprising the domain was added to the culture-wells immediate before seeding of cells. Fig. 14 shows the mean length of the longest neurite measured 21 h after seeding of primary hippocampal neurones in the presence of NCAM Ig2 25 polypeptide (pLoop2") in the indicated concentrations. It shows that NCAM Ig2 stimulates neurite outgrowth with a bell-shaped dose-response relationship similar to that of the C3 peptide. The maximal neuritogenic effect of 30 NCAM Ig2 was found at a concentration of 5.4 μ g/ml which corresponds to 0.54 μ M of the domain. This is the same 35

concentration at which the C3 peptide had a maximal neuritogenic effect. The NCAM Ig2 domain was then tested in combination with compounds known to inhibit NCAM dependent signalling as described for C3 above. These 5 compounds also inhibited the neuritogenic effect of NCAM Ig2. Thus, NCAM Ig2 and C3 both binds to NCAM Ig1 and both NCAM Ig2 and C3 stimulate neurite extension by activating identical signal transduction pathways. Therefore, NCAM Ig2 and C3 were tested for their effect 10 on neurite outgrowth when added in combination. The effect of NCAM Ig2 was found to be non-additive to that of C3 (Fig. 15). The results shown that NCAM Ig2 and C3 stimulate neurite extension by identical mechanisms. They both bind the NCAM Ig1 domain and thereby activate 15 identical signalling pathways leading to neurite outgrowth.

EXAMPLE 8

20 Proliferation

Cell proliferation was determined by incorporation of 5-bromo-2'-deoxyuridin in a cell proliferation ELISA system (Amersham Life Science) according to the procedure of the manufacturer. Primary hippocampal neurones were seeded in 25 microtiter plates at a density of 33000 cells per well. In the presence of C3d in a concentration of 0.8 μ M, an increased incorporation of BrdU was observed indicating a stimulation of neuronal proliferation. The dose-response curve was bell-shaped (Fig. 16), thus at higher 30 concentrations, C3 inhibited proliferation. C3 also promoted proliferation of neuroblastoma cells. However, the net effect on proliferation depended on the growth status of cell. Hence in PC12 cells, an inhibitory effect on proliferation was observed concomitant with an increased neurite outgrowth indicating that the peptide 35 stimulated differentiation of these cells. These results

show that NCAM Ig1 binding compounds can influence proliferation of neurones. The net effect depends on the growth status of the cells but under the proper circumstances, a stimulation of proliferation will result.

5

EXAMPLE 9

Cell growth

10 Cell growth is another way of monitoring proliferation of the cells. Primary hippocampal cells were seeded into 96 well microtiter culture plates (Nunc A/S) at a density of 20.000 or 40.000 per well in defined medium as described above. Cells were grown for 48 h, centrifuged in order to
15 remove medium, fixed in 3.7% formaldehyde in PBS for 15 min and stained with 0.5% Cristal Violet in 20 % methanol for 15 min. Stained cells were thoroughly washed with Milli Q purified water, thereafter residual dye was solubilised with 0.1 M sodium citrate in 50% ethanol pH 4.2 and
20 absorbance measured at 550 nm. When added in 0.8 μ M immediately preceding seeding of cells, C3 was shown to increase cell growth.

References

Andersson AM. Biochemical Journal 1993; 290:641-8.

5 Beggs, H.E. N Journal of Biological Chemistry 1997, 272, no. 13: 8310-8319.

Carenini S. Cell & Tissue Research 1997; 287:3-9.

Cremer H Molecular & Cellular Neurosciences 1997; 8:323-35.

10 Cremer H. Nature 1994; 367:455-9.

Daniloff JK. Journal of Cell Biology 1986; 103:929-45.

Daston MM. Journal of Neuroscience 1996; 16:5488-97.

Doherty P. Nature 1992; 356:791-3.

Doherty P. Molecular and Cellular Neuroscience 1996; 8:99-111.

15 Doyle E. Journal of Neuroscience Research 1992; 31:513-23.

Edelman GM Cold Spring Harbor Symposia on Quantitative Biology. Cold Spring Harbor Laboratory Press, 1990: 303-18.

20 Fazeli S. Seminars in the Neurosciences 1997; 8:367-77.

Fields RD. Trends in Neurosciences 1996; 19:473-80.

Frei T. Journal of Cell Biology 1992; 118:177-94.

Furka, A. International Journal of Peptide & Protein Research 1991; 37: 487-493.

25 Gaardsvoll H. European Journal of Cell Biology 1993; 61:100-7.

Horstkorte R. The Journal of Cell Biology 1993; 121, no 6:1409-21.

30 Jucker M. Brain Research 1995; Molecular Brain Rese:149-56.

Kasper C. Journal of Neuroscience Research 1996; 46:173-86.

Kiselyov V. Journal of Biological Chemistry 1997, 272: 35 10125-10134.

Knittel T. American Journal of Pathology 1996;

149:449-62.

Krushel LA. Proceedings of the National Academy of Sciences of the United States of America 1998; 95:2592-6.

Lackie PM. Development 1990; 110:933-47.

5 Lahrtz F. Journal of Neuroscience Research 1997; 50:62-8.

Lam, KS. Nature 1991, 354: 82-84.

Lam, KS. Immunomethods 1992, 1, 11-15.

Landmesser L. Neurone 1990; 4:655-67.

10 Luthi A. Nature 1994; 372:777-9.

Maar, TE. Journal of Neuroscience Research 1997, 47: 163-172.

Massaro AR. Italian Journal of Neurological Sciences 1987; Suppl 6:85-8.

15 Moller CJ. Anatomy & Embryology 1991; 184:541-8.

Moller CJ. Molecular Endocrinology 1992; 6:1332-42.

Nieke J. Differentiation 1985; 30:141-51.

Olsen M. Int J Devl Neuroscience 1995; 13:97-104.

Ono K. Neurone 1994; 13:595-609.

20 Pollerberg GE. Developmental Biology 1993; 156(2):324-40.

Rabinowitz JE. Proceedings of the National Academy of Sciences of the United States of America 1996; 93:6421-4.

Ranheim, T.S. Proceedings of the National Academy of Sciences of the United States of America 1996, 93: 4071-25 4075.

Rao Y. Journal of Cell Biology 1992; 118:937-49.

Rao Y. Journal of Biological Chemistry 1994; 269:27540-8.

Romanska HM, Journal of Pediatric Gastroenterology &

30 Nutrition 1996; 22:351-8.

Rønn LC. Brain Research 1995; 677:145-51.

Rønn LC. Ph.D.thesis; The Protein Laboratory and The Division of Neurophysiology, University of Copenhagen 1997.

35 Rutishauser U. Trends in Neurosciences 1996; 19:422-7.

Sandig M. Journal of Biological Chemistry 1994;

269:14841-8.

Sanes JR. Journal of Cell Biology 1986; 102:420-31.

Scholey AB. Neuroscience 1993; 55:499-509.

Schuch U. Neurone 1989; 3:13-20.

5 Shen H. Journal of Neuroscience 1997; 17:5221-9.

Stahlhut M. Journal of Neuroscience Research 1997; 48:112-21.

Stork O. European Journal of Neuroscience 1997; 9:1117-25.

10 Thomsen NK. Nature Structural Biology 1996; 3:581-5.

van Kammen DP. Biological Psychiatry 1998; 43:680-6.

Walsh FS. Neuroscience Letters 1985; 59:73-8.

Zhang H. Journal of Neuroscience 1992; 12:3107-14.

Claims

1. A compound which binds to the NCAM Ig1 domain and is capable of stimulating neurite outgrowth from and/or proliferation of NCAM presenting cells.
- 5
2. A compound of claim 1 which compound is the NCAM Ig2 polypeptide or a fragment thereof or a mimic thereof.
- 10
3. A compound of claim 2 which compound is the NCAM Ig2 polypeptide.
4. A compound of claim 2 which compound is a fragment of the NCAM Ig2 domain.
- 15
5. A compound of any of claims 2-4 which compound is a peptide which binds to the NCAM Ig1 domain through a binding motif which comprises at least 2 basic amino acid residues.
- 20
6. A peptide of claim 5 which comprises at least 2 basic amino acid residues within a sequence of 10 amino acid residues.
- 25
7. A peptide of claim 6 which comprises at least 2 basic amino acid residues within a sequence of 3 amino acid residues.
8. A peptide of any of claims 4-7, characterised in that it comprises the sequence:
- 30

$$(Xaa^+)_m - (Xaa)_p - (Xaa^+) - (Xaa^1)_r - (Xaa^+) - (Xaa)_q - (Xaa^+)_n ,$$

wherein Xaa^+ is a basic amino acid residue,
35 Xaa^1 is any amino acid residue,
 Xaa is any amino acid residue, and

m, n, p, q and r independently are 0 or 1.

9. A peptide according to any of claims 5-8 wherein the basic amino acid residues are lysine (K) or arginine (R).

5
10. A peptide according to any of claims 5-9 wherein r is 1.

10. 11. A peptide according to claim 10 wherein Xaa¹ is proline (P) or glutamic acid (E).

12. A peptide according to any of claims 5-11 wherein at least one of m and n is 1.

15
20. 13. A peptide according to claims 5-12 wherein the peptide comprises the sequence (K/R)0-1-K/R-X-K/R), wherein X has the meaning Xaa¹, suitably the sequence K/R-K/R-X-K/R or K/R-X-K/R, more suitably the sequence K/R-P-K/R, K/R-K/R-P-K/R, K/R-K/R-E-K/R or K/R-K/R-E-K/R, even more suitably the sequence K-P-K, K-K-P-K, K-K-E-K or K-K-E-R and most suitably the sequence A-S-K-K-P-K-R-N-I-K-A (SEQ ID NO:1), A-K-K-25
E-R-Q-R-K-D-T-Q (SEQ ID NO:2), or A-R-A-L-N-W-G-A-K-P-K (SEQ ID NO:3).

30
14. A peptide according to claim 13 which peptide has the sequence A-S-K-K-P-K-R-N-I-K-A (SEQ ID NO:1), A-K-K-E-R-Q-R-K-D-T-Q (SEQ ID NO:2), or A-R-A-L-N-W-G-A-K-P-K (SEQ ID NO:3).

15. A peptide according to any of claims 5-14 wherein one or more of the amino acid residues is modified, such as being acetylated.

16. A peptide according to any of the claims 5-15, which peptide is identical to a part of the NCAM Ig2 domain.
- 5 17. A peptide according to any of the claims 5-15, which peptide is a mimic of the NCAM Ig2 domain or of a fragment of the NCAM Ig2 domain.
- 10 18. A peptide according to any of claims 5-17, which peptide binds to the NCAM Ig2 binding site on the NCAM Ig1 domain.
- 15 19. A peptide according to any of claims 5-17, which peptide binds to a binding site on the NCAM Ig1 domain, which binding site is different from the NCAM Ig2 binding site.
- 20 20. A compound according to claim 2, which compound is a non-peptide molecule mimicking the binding of the NCAM Ig2 domain or a fragment thereof of a peptide mimic thereof to the Ig1 domain.
- 25 21. A compound according to claim 2, which compound is an anti-NCAM Ig1 antibody.
22. An antibody according to claim 21, which antibody is monoclonal.
- 30 23. An antibody according to any of claims 21 or 22, which antibody is chimeric or humanised.
- 35 24. The NCAM Ig2 polypeptide, a fragment or a mimic thereof according to any of claims 1-23 for use in the treatment of normal, degenerated or damaged NCAM presenting cells.

25. The NCAM Ig2 domain or a fragment or mimic thereof for use in the treatment according to claim 24, wherein the treatment consists of stimulating outgrowth from and/or proliferation of the NCAM presenting cells.
- 5
26. The NCAM Ig2 domain or a fragment or mimic thereof for use in a treatment according to claims 24 or 25 wherein the treatment is a treatment of diseases and conditions of the central and peripheral nervous system, of the muscles or of various organs.
- 10
27. The NCAM Ig2 domain or a fragment or mimic thereof for use in a treatment according to claim 26 wherein the treatment is a treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia.
- 15
- 20
- 25
28. The NCAM Ig2 domain or a fragment or mimic thereof for use in a treatment according to claim 26 wherein the treatment is a treatment of diseases of muscles including conditions with impaired function of neuro-muscular connections such as genetic or traumatic atrophic muscle disorders.
- 30
29. The NCAM Ig2 domain or a fragment or mimic thereof for use in a treatment according to claim 26 wherein the treatment is a treatment of diseases of various organs, such as degenerative conditions of the
- 35

gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart, liver and bowel.

- 5 30. The NCAM Ig2 domain or a fragment or mimic thereof for use in a treatment according to claim 24 or 25 wherein the treatment is a stimulation of ability to learn and/or of the memory.
- 10 31. Use of the NCAM Ig2 domain or a fragment or mimic thereof according to any of the claims 1-23 in the manufacture of a medicament for the treatment of normal, degenerated or damaged NCAM presenting cells.
- 15 32. Use according to claim 31 wherein the treatment is a stimulation of neurite outgrowth from and/or proliferation of NCAM presenting cells.
- 20 33. Use according to any of claims 31 or 32 wherein the medicament is for treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, 25 Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; for treatment of diseases or 30 conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; or for treatment of diseases or conditions of various organs, such as degenerative conditions of the 35 gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of

the heart, liver and bowel.

34. Use according to any of claims 31 or 32 wherein the medicament is for the stimulation of the ability to 5 learn and/or of the memory.
35. Pharmaceutical composition comprising one or more of the compounds according to any of the claims 1-23.
- 10 36. Composition according to claim 35 wherein the compound is the NCAM Ig2 domain or a fragment thereof or a peptide mimic thereof.
- 15 37. Composition according to claim 36 wherein the peptides are formulated as multimers.
- 20 38. Composition according to claim 37, characterised in that the peptides are formulated as dendrimers, such as four peptides linked to a lysine backbone, or coupled to a protein carrier such as BSA.
- 25 39. A method of treating normal, degenerated or damaged NCAM presenting cells in vitro or in vivo, characterised in that an effective amount of one or more of the peptides according to claims 1-23 or a composition according to claims 35-38 is administered in vitro or in vivo.
- 30 40. A method of claim 39 wherein the treatment is a stimulation of neurite outgrowth from and/or proliferation of NCAM presenting cells.
- 35 41. A method of any of claims 39 or 40 wherein the treatment is an in vivo treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic

nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve

5 degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; of diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections,

10 such as genetic or traumatic atrophic muscle disorders; or of diseases or conditions of the organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of

15 the heart, liver and bowel.

42. Method according to any of claims 39-41 wherein the treatment leads to regeneration of nerves.

20 43. Method according to claim 42 wherein the compounds are used in combination with a prosthetic device.

44. Method according to claim 43 wherein the device is a prosthetic nerve guide.

25 45. A prosthetic nerve guide, characterised in that it comprises one or more of the compounds according to claims 1-22 or a composition according to claims 32-36.

30 46. Method of stimulating the ability to learn and/or the memory in a subject, characterised in that an effective amount of one or more of the compounds according to claims 1-22 or a composition according to claims 35-38 is administered to said subject.

35

47. Medicament for the treatment of diseases and conditions of the central and peripheral nervous system, of the muscles or of various organs, characterised in that the medicament comprises an effective amount of one or more of the compounds according to claims 1-22 or a composition according to claims 35-38 and one or more pharmaceutically acceptable additives or carriers.

5

10 48. Medicament according to claim 47, formulated for oral, percutaneous, intramuscular, intracranial, intraventricular, intranasal or pulmonal administration.

15 49. Composition for use in the stimulation of learning and/or memory in a subject, characterised in that the composition comprises an effective amount of one or more of the compounds according to claims 1-22 or a composition according to claims 35-38 and one or more pharmaceutically acceptable additives or carriers.

20

25 50. Composition according to claim 49 formulated for oral, percutaneous, intramuscular, intracranial, intraventricular, intranasal or pulmonal administration.

Abstract

The invention relates to treatment of diseases and conditions of the central and peripheral nervous system, treatment of diseases and conditions of muscles and treatment of diseases and conditions of various organs. The treatment may also be a stimulation of learning and memory. In particular, the present invention concerns new compounds which are capable of stimulating proliferation of and/or neurite outgrowth from cells presenting the neural cell adhesion molecule (NCAM), such as neurones. In a further aspect, the present invention relates to pharmaceutical compositions and medicaments as well as methods for treating normal, degenerated or damaged NCAM presenting cells.






FIG. 1

2/17

A

B



C




FIG. 2

Modtaget PD
SEP. 1998

3/17





FIG. 3

29 SEP. 1998

4/17


A	A R A L N W G A K P K A G S A V K L K K K A A K Y V L I P I R I S A S T K R S M Q G I - A R R A I L M Q I A I A Y Y L I V R V N R I A T N K K T G R R P R A K R N G P L I N R I A K R S V Q K L D G Q A R Q K T M K P R R S A G D Y N P D L D R - A S K K P K R N I K A A R K T R E R K S K D A S Q A K R R K G P R A P K L D R M I T K K A K K E K P N K P N D A Q M G R Q S I D R N A E G G K K K K M R A A K K E R Q R K D T Q A K K E Q K Q R N A A K S R K G N S S L M A R K S R D M T A I K
B	C3 A S K K P K R N I K A A T N K K T G R R P R A R A L N W G A K P K A R Q K T M K P R R S A K R S V Q K L D G Q A S T K R S M Q G I -
C	D3 A K K E R Q R K D T Q A K K E K P N K P N D A R K T K S R E R K D
D	D4 A R A L N W G A K P K A T N K K T G R R P R

FIG. 4

Modtaget PD
29 SEP. 1998

5/17


FIG. 5



Modtaget PD
29 SEP. 1998

6/17

FIG. 6



23 SEP. 1998

7/17

Controls for NCAM Ig1 binding peptide (C3)

Peptide	Sequence										Effect*
	Neur					agg					
C3	A	K	K	P	K	R	R	A	A	A	++
C3acetyl, K(120) A	S	K#	K#	P	K#	R	R	A	A	A	++
Ala subst K/R	S	K	K	P	K	A	N	I	I	I	--
116	A	S	K	P	A	A	N	I	I	I	--
117	A	S	K	P	A	A	N	I	I	I	--
118	A	S	K	P	A	A	N	I	I	I	--
119	A	S	K	P	A	A	N	I	I	I	--
P>A											--
122	A	S	K	A	K	R	N	I	K	A	++
Scrambled C3	A	K	K	K	R	I	S	K	K	A	++
121	P	N	A	S	P	R	R	K	I	K	++
114	P	N	S	P	K	A	R	R	K	D	++
C3ser	K	K	E	R	Q	D	K	Q	E	R	++
D3	A	K	T	K	Q	N	W	A	K	P	++
scrabbed D3	R	T	A	L	R	W	A	K	K	K	++
D4	A	R	K	R	W	A	K	K	K	K	--
Scrambled D4	G	L	K	R	W	A	K	K	K	K	--
Poly-K											--
K6 (dendrimer 11.5)	K	K	K	K	K	K	K	K	K	K	+

* effect on neurite extension (neur) and aggregation (agg)


acetylation on lysine

FIG. 7

Modtaget PD
29 SEP. 1998


8/17

FIG. 8



9/17


FIG. 9



29 SEP. 1998

10/17

FIG. 10

10/2-97x hip E18 fibronect 20 μ g/ml 2h 37C

Maget PD
29 SEP. 1998

11/17

FIG. 11

15/5-97 hip E18 plastic





FIG. 12

15/5-97 hip E18 fibronectin




13/17

FIG. 13

erb: erbstatin analog, CHD: camhomoldom. peptid (#126)
pertus: pertussis toxin


20/5-97 hip E18 fibronect 10 μ g/ml, airdried



14/17

FIG. 14


15/5-97 hip E18 fibronectin



29 SEP. 1998


15/17

FIG. 15



16/17

FIG. 16



29 SEP. 1998

17/17

1 MLIQTKDOLIWT LFFLGLTAVSL QVDIVPSQGE ISVGESKFFL CQVAGDAKDK DISWFSPNGE
61 KLTPNQQRIS VVWNDDSSST LTIYNANIDD AGIYKCVUTG EDGSESEATV NVKTFOKLME
121 KNAPTPQEFR EGEDAVIVCD VVSSLPPTII WKHKGRDVIL KKDVRFTVLS NNYLQIRGIK
181 KTDEGYRCE GRILARGEIN FKDIQVIVNV PPTIQARQNI VMATANLGS VTLVCDAEGR
241 PEPTMSWTKD GEQLEQEEED EKVIFSDSSS QLTIKKVDKN DEAEYICIAE NKAGEQDATI
301 HLKVFAKPKI TYVENQTAIE LEEQVTLTCE ASGDPIPSIT WRTSTRNIS EEKTLGDMV
361 VRSHARVSSL TLKSIQYTDI GEYICTASNT IGQDQSMSYL EVQYAPKLG PVAVYTWEQN
421 QVNITCEVFA YPSATISWFR DGQLLPPSNY SNIKIYNTPS ASYLEVTPDS ENDFGNYNC
481 AVNTRIGQESL EFLVQADTP SSSPSIDQVEP YSSSTAQVQFD EPEATGGVPI LKYKAEWRAV
541 GEEVWHSKWY DAKEASMEGI VTIVGLKPET TYAVRILAALN GKGELGEISAA SEFKTQPVQG
601 EPSAPKLEGQ MGEDGNSIKV NLIKQDDGGS PIRHYLVRYR ALSEEWKPEI RLPSSGSDHVM
661 LKSLDWNAY EVYVVAENQQ GKSKAHAHFV RTSAQPTAIP ANGSPTSGLS TGAIVGILLIV
721 IFVLLLVVVD ITCYFLNKG LFMCIAVNL GKAGPGAKGK DMEEGKAAFS KDESKEPIVE
781 VRTEEEERTPN HDGGKHTEPN ETTPLTEPEK GPVEAKPECQ ETETKPAAE VKTVPNDATO
841 TKENESKA

FIG. 17

